Citigroup Maintains Neutral on Amgen, Raises Price Target to $405

Benzinga Newsdesk www.benzinga.com Neutral 51.0%

Neg 0% Neu 51% Pos 0%

Citigroup analyst Geoff Meacham maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $345 to $405.